Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.53 |
| ▸ | NPY1R | P25929 | 10/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.53 |
| ▸ | NPY2R | P49146 | 6/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.46 |
| ▸ | TFPI | P10646 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4450831 | 0.93 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL4447313 | 0.92 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL10027651 | 0.89 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL4457775 | 0.89 | CTSK (0.58) | NPY4RNPY1RNPY5RNPY2RCTSB | |
| SCHEMBL16181257 | 0.87 | FURIN (0.53) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL334150 | 0.85 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RCTSB | |
| SCHEMBL30423373 | 0.84 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16181241 | 0.83 | FURIN (0.55) | TFPI | |
| SCHEMBL6035200 | 0.83 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29625333 | 0.82 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097582-B2 | Peptide derivatives useful as antimicrobial agents and for treating wounds | NEOBIOTICS AB (SE) | 2012-01-17 | — | — | US | disclosed |
| US-8097582-B2 | Peptide derivatives useful as antimicrobial agents and for treating wounds | NEOBIOTICS AB (SE) | 2012-01-17 | — | — | US | disclosed |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | ZULA DIAGNOSTICS AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | ZULA DIAGNOSTICS AB (SE) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118198-A1 | NOVEL PEPTIDE DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS FOR TREATING WOUNDS | VIP, NGLY1, ARG1 | NPY4R 488/4885NPY1R 315/4885NPY5R 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.